Killian Meara

A Q&A with Douglas Hoey, CEO of NCPA, on ways to change the pharmacy payment model and deceptive practices being employed by PBMs.

Abeona Therapeutics’ pz-cel is an investigational autologous, COL7A1 gene-corrected epidermal sheet therapy for the treatment of recessive dystrophic epidermolysis bullosa.

At AAP 2024, Kathy Campbell, PharmD, discussed obstacles that pharmacies may face when transitioning to a wellness-focused approach.

A higher patient-rated therapeutic alliance was associated with improvements in depression outcomes up to 1 year after treatment.

Check out important updates from the FDA for the week of April 15.

A Q&A with Joe McKamey, general manager at Marcrom’s Pharmacy in Manchester, Tennessee.

Nine pharmacists from 2 corporate locations in Wakefield and Westerly are seeking to join the Pharmacy Guild in an attempt to improve working conditions.

Kathy Campbell, PharmD, discusses why she believes wellness and proactive health are the future of pharmacy and the unique value they offer compared to traditional models.

Patients in ED being treated for an opioid overdose were more likely to initiate medication for opioid use disorder after discharge when they received peer recovery support services.

A Q&A with Douglas Hoey, CEO of NCPA, on how the new provision from CMS requiring DIR fees at the point of sale is impacting independent pharmacies in 2024.

The ongoing opioid crisis in the United States shows no signs of slowing down. As trusted community health care professionals, pharmacists must play a key role in fighting it.

A study from the Karolinska Institutet found that 76 out of 145410 patients treated with a GLP-1 developed thyroid cancer during nearly 4 years of follow-up.

A study from the Children’s Hospital of Philadelphia found that a positive PCR test was not associated with an increased risk of a new asthma diagnosis in patients ages 1 to 16.

In the United States, 12 million adults suffer from co-occurring chronic pain and anxiety or depression. Erasing stigmas, educating patients, and tailoring interventions can help to improve outcomes.

After a long hiatus, research in psychedelic medicine is progressing rapidly. With the potential approval of MDMA in the near future, what role will pharmacists play in integrating these new therapies into treatment plans?

At AAP 2024, the Cardinal Health Pharmacy Transitions Services team hosted a session outlining how best to go about selling and buying a pharmacy.

Joe McKamey, general manager at Marcrom’s Pharmacy, highlights the potential pitfalls or misconceptions that pharmacies may encounter when opening a Medicare-focused insurance agency.

Eric Fromhart, co-founder and chief growth officer at Aventi Health, discusses how pharmacies can use 340B to increase profits and how they can avoid any potential risks when participating in the program.

Brian Rakers, senior vice president of distribution and member support at Pharmacists Mutual Insurance Group, talked cybersecurity during a session at AAP 2024.

In an interview at AAP 2024, Douglas Hoey, CEO of NCPA, talked about changing the pharmacy payment model and deceptive practices being employed by PBMs.

Joe McKamey, general manager at Marcrom’s Pharmacy in Manchester, Tennessee, talks about why pharmacies should open their own Medicare-focused insurance agency and what steps and preparations they can take to ensure a successful launch and operation.

Kathy Campbell, PharmD, pharmacist and patient advocate at Medicap Pharmacy in Owassa, Oklahoma, and CEO of DrKathy Health, discusses the unique value that a wellness-focused pharmacy offers compared to traditional models.

Eric Fromhart, co-founder and chief growth officer at Aventi Health, talked about the importance of the 340B drug pricing program at the 2024 AAP annual conference.

Drug Topics sat down with Douglas Hoey, CEO of NCPA, at the 2024 AAP annual conference to discuss how independent pharmacies are doing so far this year.

This year’s conference, which is being held April 4 to 6 in San Diego, California, features talks from industry experts on developments in the pharmacy field, actionable skills, and informative CE sessions.

Priovant Therapeutics said that it intends to initiate a phase 3 program of brepocitinib in the second half of this year.

Rejoyn from Otsuka Pharmaceutical and Click Therapeutics is a 6-week program that helps enhance cognitive control of emotions through brief therapy lessons and training exercises.

The can’t-miss event on April 13 features speakers and CE sessions focused on elevating patient-centric care.

The approval of vadadustat (Vafseo) from Akebia Therapeutics was based on data from the phase 3 INNO2VATE program.

Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.